Glioblastoma Targeted Treatment Option Maximization by WGS
Netherlands164 participantsStarted 2022-07-25
Plain-language summary
In Dutch centers performing neurosurgery on and/or treating GBM, all recurrent GBM patients are discussed in local tumor boards and this setup will be used to effectively identify possible GLOW study candidates. 160 patients that will undergo re-resection in the GLOW study will be presented with WGS results leading to added treatment options.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Histopathologically confirmed IDH wild type glioblastoma, first recurrence after standard chemoradiation; suitable for standard-of-care re-resection;
. Age ≥ 18 years;
. Able and willing to give written informed consent;
. Life expectancy \>3 months, allowing adequate follow-up of toxicity evaluation and antitumor activity;
. KPS performance status ≥70.
Exclusion criteria
. Currently actively treated in another antitumor clinical trial (excluding DRUP and STELLAR studies);
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial used whole genome sequencing to try to maximize targeted treatment options for glioblastoma — can you explain whether my tumor would have been a good candidate for that kind of approach, and whether similar genomic profiling is available to me now?
2Since this trial is completed and was measuring overall survival, has any data been published yet, and if so, what did it suggest about whether WGS-guided treatment made a difference compared to standard care?
3Whole genome sequencing can reveal many different mutations — if my tumor were sequenced this way, how would you use those results to decide which targeted therapies, if any, might be worth trying in my case?
4Because this trial is listed as 'Phase NA,' it may have been more of an observational or feasibility study rather than a randomized treatment trial — does that affect how much we can rely on its findings when thinking about my treatment plan?
5Are there currently open clinical trials or standard-of-care options that already incorporate genomic sequencing for glioblastoma, so we could still explore a targeted approach similar to what this trial was investigating?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
. Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in medication studies or which could jeopardize compliance with study requirements including, but not limited to ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.